232 results about "Antibody antigen" patented technology

The invention discloses an oxidized low-density lipoprotein detection method and oxidized low-density lipoprotein detection equipment based on magnetic microsphere luminescence, and the method comprises the following steps: carrying out alkaline phosphatase labeling on an oxidized low-density lipoprotein antibody by using the oxidized low-density lipoprotein antibody, carrying out mixed reaction on the other antibody and modified carboxyl / toluenesulfonyl microspheres, and carrying out separation and purification to obtain a target product, a chemiluminescence immunoassay system is constructed, and oxidized low-density lipoprotein antigens in a sample, enzyme-labeled antibodies and labeled magnetic beads form a'magnetic bead-antibody-antigen-enzyme-labeled antibody 'compound. Then, through a two-step cleaning process, an optical signal value RLU is generated under the action of a light-emitting substrate APS-5, and finally, the optical signal value is amplified by a photomultiplier tube PMT in light-emitting equipment. According to the scheme, the specificity can be improved from the sample capturing end, and the sensitivity can be enhanced at the signal processing end.

Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).

The present invention discloses a hs-TnI detection method based on quantum dot microspheres, which directly reacts a sample with a first solution containing antibody 1 and a second solution containing antibody 2 to generate a sandwich structure complex of antibody 1-antigen-antibody 2, and the antigen and antibody react in a reaction cup, incubate at a constant temperature, and the reaction time is longer, and the reaction is more sufficient, which is conducive to the improvement of detection sensitivity. At the same time, during chromatography, with the high affinity of streptavidin and biotin, the complex obtained by the reaction can be better captured on the T line, so that the reaction can be made more sensitive, and the detection time is also faster relative to the existing reagent strips. Further, combined with the advantages of high sensitivity and wide linear range of quantum dot microspheres, detection repeatability (CV) is better, CV is increased from the traditional 15wt% to within 8wt%, and the detection sensitivity is as high as 2pg / ml, while the linear range is 2-30000pg / ml, and full coverage is achieved for low-concentration and high-concentration samples.

A protein interface prediction method based on three-track coding comprises the following steps: combining a fine-tuned protein language model SiteT5 with evolutionary, geometric and statistical features extracted from a sequence, sending the combined features into a three-track coding network, and integrating a cyclic gating module, a multi-resolution aggregation module and a long sequence deformation module to obtain a protein interface prediction model SiteT5; the method comprises the following steps: respectively capturing a time sequence relation, a local mode and long-range dependence among residues, respectively mapping the three codes into different weights, carrying out point multiplication on the three codes, and carrying out aggregation through a multi-view cross attention module; then the protein residues are sent to a three-layer hierarchical interactive learning module, local structure and global dependency are cooperatively mined through an eight-head gating self-attention module and a position-by-position feedforward module, and finally the probability that each protein residue is an interface is obtained through a classifier. According to the invention, a protein-DNA interface, a protein-RNA interface, a protein-protein interface and an antibody-antigen interface can be effectively captured. And the robustness is ensured, and meanwhile, relatively high prediction precision is also shown.

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

The invention discloses a Fel D1 and Fel D4 fusion protein and application thereof, the Fel D1 and Fel D4 fusion protein is obtained in a prokaryotic expression mode, the fusion expressed protein greatly simplifies operation procedures in the aspects of inducing protein expression, purification, concentration, immunization and the like, and the economic cost is reduced. According to the preparation method of the egg yolk antibody provided by the invention, the egg yolk antibody obtained through fusion protein immunization laying hens can be subjected to antibody-antigen reaction with Fel D1 and Fel D4 respectively, and the titer of the egg yolk antibody is higher than that of a single antigen protein immunization group and a combined immunization group. The invention further provides a preparation method of the functional cat food, the egg yolk powder is added into the cat food according to a certain proportion, after the cat food is fed for a period of time, the content of Fel D1 and Fel D4 in cat hair and saliva is remarkably reduced, the cat food prepared from the fusion protein egg yolk antibody can resist Fel D1 and Fel D4 at the same time, and the blocking effect is remarkably improved.

The invention provides an antibody screening method and system based on a differential evolution algorithm and an artificial intelligence model. The method comprises the following steps: S1, acquiring data of an antibody-antigen compound sequence and affinity; s2, encoding the antibody and antigen sequences by using a language model, and converting the encoded antibody and antigen sequences into a matrix M; s3, training a machine learning model by using the matrix M and the affinity parameters to obtain a trained optimal machine learning model; s4, predicting the antigen affinity of the antibody by utilizing the trained optimal machine learning model; and S5, carrying out affinity optimization on the antibody sequence based on a differential evolution algorithm, and carrying out further filtration by predicting the druggability of the antibody so as to screen the antibody with high affinity and good drug properties.

The invention provides an mRNA (messenger Ribonucleic Acid) or mRNA-LNP (Leucine Natriuretic Peptide) compound for coding antibody-antigen fusion protein and application thereof, and belongs to the technical field of cell therapy. Wherein the coding frame sequence of the mRNA comprises an antibody sequence, a cleavage sequence and an antigen peptide sequence; wherein the antibody targets a tumor high-expression surface protein, and the antigen is a high-immunogenicity antigen. According to the mRNA-coded antibody-antigen fusion protein, high-expression protein on the surface of a tumor cell is specifically recognized through an antibody, and a high-immunogenicity antigen is introduced into a recognized tumor target cell to mark the tumor cell. The mRNA can be ingested, processed and presented by antigen presenting cells so as to stimulate and activate antigen-specific TCR-T cells in vivo. Therefore, the widely labeled tumor cells can be specifically recognized and killed by the antigen-specific TCR-T cells in vivo.

This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

The invention relates to a dog early pregnancy RLN detection kit and a detection method thereof. The kit comprises a magnetic bead working solution, an enzyme working solution, a cleaning solution, a chemiluminescent substrate, a calibration product and a quality control product. Wherein the magnetic bead working solution contains toluenesulfonyl magnetic beads labeled by canine RLN monoclonal antibodies, and the enzyme working solution contains canine RLN monoclonal antibodies labeled by alkaline phosphatase and an antibody blocking agent. When the canine early pregnancy RLN detection kit provided by the invention is used for determining the canine RLN concentration in serum, the RLN antibody on the magnetic bead and the RLN antibody on the enzyme marker are simultaneously and rapidly combined with different sites on the RLN antigen to form an antibody-antigen-antibody structure, the combination is more sufficient, the detection sensitivity is high, the antibody blocking agent shortens the window period of detection, and the detection time is shortened. The false positive of the detection result is reduced, and the detection accuracy is improved.

Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.

Antibodies and antigen-binding fragments that specifically bind to and neutralize human metapneumovirus (hMPV) F protein are disclosed. Nucleic acids, vectors and host cells encoding these antibodies are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids, and vectors can be used, for example, to inhibit or detect hMPV infection.

Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and / or treat an HIV-1 infection is disclosed.

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and / or ADC) to a CD276 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and / or ADCs) that bind to a CD276 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer are provided.

The present disclosure relates to anti-LILRB1 (leukocyte immunoglobulin-like receptor B member 1) and / or anti-LILRB2 (leukocyte immunoglobulin-like receptor B subfamily member 2) antibodies, antigen binding fragments and uses thereof.

This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Provided are an activity-regulatable IL-12 fusion protein and the use thereof. The fusion protein comprises a first structural unit, a second structural unit, and a third structural unit. The first structural unit is selected from a first Fc fragment, or a first antibody or an antigen-binding fragment thereof, wherein the first antibody or the antigen-binding fragment thereof has the binding activity to a tumor antigen or an immune checkpoint; the second structural unit is selected from a cleavable linker or a non-cleavable linker; and the third structural unit comprises an IL-12 cytokine or a functional fragment thereof. The second structural unit mediates the steric hindrance of the first structural unit to mask the activity of the IL-12 cytokine in the third structural unit, thereby reducing the toxic side effects of in-vivo use of the IL-12 cytokine. Compared with a wild-type IL-12, the fusion protein has the advantage of high safety, and can be further fused with an antibody Fab, scFv or VHH, an antigen-binding peptide or a recombinant protein, a polypeptide, etc. to obtain a multifunctional fusion protein that can be conditionally released and activated.

The application discloses a kind of vibration device for immunofluorescence method, belong to medical detection device field, the device adopts cavity, vibration unit, cooling device and sound insulation cotton, sound insulation cotton is used to reduce noise in experimental process, cooling device reduces the heat generated due to vibration, avoid the heat generated by vibration to cause the influence to sample;After energization, vibration unit forms a kind of vibration source, the vibration of slide in incubation box in cavity is driven by vibration, and then promote the exposure of fixed antigen / antibody epitope on slide, accelerate and antibody / antigen in incubation sample are combined, shorten incubation time, improve experimental efficiency.

The present invention discloses a detection substrate, detection method and equipment based on the modification of polymer passivation self-polymerizing thin film coating. A layer of self-polymerizing polymer thin film coating is modified inside the gun head, and the reaction activity is controlled by a passivating agent to reduce the background signal of the actual detection, thereby preparing a gun head modified with a specific antigen / antibody. By using an automated device matched therewith, the following experimental operations can be realized in sequence: immune reaction based on antibody-antigen recognition, washing, incubation of enzyme-labeled antibodies, catalytic signal generation substrate and color signal self-identification reading; in addition, different signal reading probes can be accurately selected, thereby realizing accurate detection according to the content and standard of the object to be detected. The present invention realizes that in the entire detection process, only the relevant corresponding reagent consumables need to be prepared and placed in the corresponding position, and the automatic detection of different objects can be satisfied by setting the corresponding program, and the target content result can be directly obtained. The equipment is portable and can be operated automatically.

Anti-TNFR2 (tumor necrosis factor receptor 2) antibodies, antigen-binding fragments, and uses thereof are provided.

This disclosure provides methods and apparatus for generating training data, training machine learning models, and analyzing biological samples. Generating training data includes: acquiring a first image of a biological sample; generating a first set of annotations for the first image based on a second image of the biological sample stained by a quantitative method that converts antibody / antigen complexes into dots; and outputting the first image and a benchmark truth including the first set of annotations as data for training a first machine learning model (“ML”) to analyze the biological sample. Furthermore, the generated (output) training data can then be used to train the ML model, and the trained ML model can be used to analyze the biological sample.

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and / or ADC) to an ENPP1 polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and / or ADCs) that bind to an ENPP1 polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer (e.g., one or more sarcomas) are provided.

The invention relates to the technical field of medical adsorbents for blood perfusion, and discloses an application of a trans-cyclooctene group adsorbent based on a biological orthogonal reaction in preparation of a circulating tumor cell clearing preparation. The adsorbent adopts sephadex microspheres as a carrier, the surface of the carrier is modified with a trans-cyclooctene (TCO) group, a tetrazine (Tz) group is taken in by CTCs through modified mannose, the Tz group is expressed on the surface of a CTCs cell membrane in the form of glycoprotein through a Roseman-Warden pathway in cells, TCO and Tz are subjected to a biological orthogonal reaction specifically, and the adsorption capacity of the adsorbent is improved. The sephadex microsphere adsorbent can effectively enrich and remove CTCs in blood of the whole body of a patient through adsorption, and compared with a conventional single-antibody or multi-antibody capture technology, the sephadex microsphere adsorbent does not depend on antibody-antigen binding, and the capture efficiency of the CTCs can be remarkably improved through a biological orthogonal reaction.

The invention discloses an up-conversion nano-composite with a core-shell structure, a preparation method and application, and belongs to the technical field of biomedical bimodal nano-probes. According to the nanocomposite, up-conversion nanoparticles (UCNPs) serve as a core, metal-organic frameworks (MOFs) serve as a shell layer, horse radish peroxidase (HRP) is loaded on the shell layer, and UCNP (at) MOF / HRP is formed. Subsequent biological functional modification, such as coupling of an antibody, an antigen, nucleic acid and other substances, can be carried by an activating group or a metal coordination bond carried by a shell ligand of the upconversion nanocomposite MOF with the core-shell structure, so that the functions of specific recognition, targeted capture, specific loading and the like are realized.

The present disclosure relates to anti-glyco-cMET antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of cMET and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The present disclosure addresses the problem of providing a therapeutic agent for a disease in which formation of tertiary lymphoid tissue occurs in a lesion.　This prophylactic or therapeutic agent for a disease in which formation of tertiary lymphoid tissue occurs in a lesion contains an anti-CD153 antibody having cytotoxicity or an antigen-binding fragment of the antibody.

This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, antibody domain, CAR, cell engager, and / or ADC) to a CD94 / NKG2A polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, antibody domains, CARs, cell engagers, and / or ADCs) that bind to a CD94 / NKG2A polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer and / or a viral infection are provided.

The present invention relates to the field of antibodies, antigen-binding fragments and immunodiagnosis. Specifically, the present invention relates to recombinant antibodies or antigen-binding fragments for binding thyroid hormone T4 (thyroxine) and halogenated bisphenol A. Furthermore, the present invention relates to isolated nucleic acid molecules comprising nucleotide sequences encoding the recombinant antibodies or antigen-binding fragments of the present invention, as well as expression vectors and host cells comprising the nucleic acid molecules of the present invention. In addition, the present invention relates to methods for producing recombinant antibodies or antigen-binding fragments for binding T4 thyroid hormone and halogenated bisphenol A, test kits and immunoassays comprising the recombinant antibodies or antigen-binding fragments of the present invention, and methods for determining the levels of T4 thyroid hormone and / or halogenated bisphenol A in a sample of a subject. Furthermore, the present invention relates to methods for processing samples, such as immunoaffinity-based sample preparation methods for enriching halogenated bisphenol A from a sample.

Methods for using antibodies, antigen-binding antibody fragments, immunoconjugates and pharmaceutical compositions for the treatment of adenoid cystic carcinoma, and pharmaceutical compositions containing immunoconjugates.

Embodiments described herein relate to systems and methods for mapping molecules into interfaces. An example interface includes a visual interface having a map visualization. Example molecules include proteins, or any protein-like molecules or fragments thereof such as antibodies, antigens, proteins, lectins, receptors. Embodiments described herein relate to systems and methods for mapping molecules into interfaces by processing data using dimensionality reduction to generation representations of molecule maps (e.g. map visualizations).